Navigation Links
BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
Date:8/19/2008

Ygiene(TM) Hospital Grade antimicrobial sets the new global standard to

eradicate (100% kill) in seconds the most difficult and lethal microorganisms commonly found in health care facilities, including MRSA and

C. difficile

NEWARK, N.J., Aug. 19 /PRNewswire/ -- BioNeutral announces successful testing of its Ygiene(TM) Hospital Grade antimicrobial against antibiotic-resistant microorganisms and spore forms of microorganisms which represent the major source of hospital acquired infections. In the US, Methicillan Resistant Staphylococcus Aureus (MRSA), Vancomycin-resistant Enterococci, Pan-resistant Klebsiellia pneumoniae and Clostridium difficile are but a few of the various lethal microorganisms present in hospital environments which contribute to over two-and-a-half million hospital acquired infections and one-hundred-thousand deaths annually. Using Ygiene(TM) Hospital Grade antimicrobial to routinely disinfect all areas in health care facilities can save many lives and billions of dollars annually in this global problem. Ygiene(TM) Hospital Grade antimicrobial has been found to completely eradicate these harmful microorganisms in seconds, and is still safe for the environment.

Dr. Philip Tierno, Principal Investigator and Head of Microbiology and Immunology at the Langone NYU Medical Center, has stated regarding Ygiene(TM) Hospital Grade antimicrobial: "No chemical formulation I have ever tested gives a quicker and more complete kill, has a broader spectrum of activity and is more 'green.'"

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated, "Despite the use of Lysol(R), Clorox(R) bleach, Oxivir(TM)Tb, Medica DC Germicidal Solution, Asepticare(R) TB+II, Germ Control 24 by Pure Biosciences and many other commercial disinfectants, the epidemic of infections continues in health care facilities. Most of these products are not sporicidal and either have no effect on the more difficult organisms,
'/>"/>

SOURCE BioNeutral Laboratories Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
2. Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
3. St. Lukes Episcopal Hospital to Add CyberKnife System to Treatment Offerings
4. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
5. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
6. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
7. Isabel Healthcare Adds Hospitals in Wisconsin & Minnesota
8. Low-Power Ultra Wideband (UWB) Technology Best RFID Choice for Hospitals to Minimize Interference Threat
9. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
10. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
11. Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... matrix for dry state room temperature transport and ... ... GenVault Corporation, the,leader in dry, room temperature biosample management, ... DNA is a,proprietary inorganic matrix with built-in oxidative protection and,antimicrobial ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... from October 13-14, 2008 at the Waldorf Astoria,in ... Officer, will,provide an overview of the company on ... About Pharmasset, Pharmasset is a clinical-stage pharmaceutical ...
... Colo., Oct. 8 GeneThera, Inc.,(Pink Sheets: GTHR), ... Chairman and CEO, Dr. Tony Milici, is featured ... The interview gives viewers an overview of ... press release., To view the clip ...
Cached Biology Technology:GenVault Corporation Launches GenTegra(TM) DNA 2GenVault Corporation Launches GenTegra(TM) DNA 3[video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.net's 3-Minute Press Show 2
(Date:10/22/2014)... 2014 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its third quarter ended September 30, 2014. ... $6.0 million, an increase of 40% compared to $4.3 million ... third quarter of 2014 was $4.1 million compared to $1.0 ... in the current three month period was primarily due to: ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... with the most commonly performed weight-loss surgery appears to ... but serious complication, according to a study published in ... Robotic Surgery. Minimally-invasive surgeons at The University ... times, length of hospital stay and complications in 605 ...
... Health Science Center at Houston plans to scan the genomes ... why blood pressure often increases as young adults age. ... funded with a new $1.1 million grant from the Genes, ... Health. The grant was one of six announced today during ...
... treatment for depression could soon be only a ... National Space Biomedical Research Institute (NSBRI) are developing ... in recognizing and effectively managing depression and other ... to crew safety and mission operations during long-duration ...
Cached Biology News:Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2Scientist plans to test for blood pressure genes affected by age 2Coming soon: Self-guided, computer-based depression treatment 2Coming soon: Self-guided, computer-based depression treatment 3
... Intracellular (IC) Fixation Buffer, used in ... No. 00-8333), can be used to ... performing intracellular staining of cytokines and ... solutions have been specially formulated for ...
... Perm Buffer III ... following fixation of PBMCs ... for staining for intracellular ... markers simultaneously. Applications: ...
Permeabilization Solution, 5X...
Perm/Wash Buffer 250 Tests...
Biology Products: